TURKISH JOURNAL OF HEMATOLOGY, vol.36, pp.230-237, 2019 (SCI-Expanded)
Objective: The aim of the present study was to evaluate the efficacy and safety of eltrombopag, an oral thrombopoietin receptor agonist, in patients with chronic immune thrombocytopenia (ITP).